Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol

Introduction Patients with metastatic or locally advanced, non-resectable, grade 3 poorly differentiated gastroenteropancreatic (GEP) and lung neuroendocrine carcinomas (NECs) are usually treated with in first-line platinum compounds. There is no standard second-line treatment on progression. Accura...

Full description

Bibliographic Details

Published in:	BMJ Open
Main Authors:	Ivan Lolli, Daniele Santini, Rossana Berardi, Giuseppe Badalamenti, Toni Ibrahim, Alfredo Berruti, Alberto Bongiovanni, Chiara Liverani, Sara Pusceddu, Silvana Leo, Giovanni Di Meglio, Stefano Tamberi, Fabio Gelsomino, Francesca Pucci, Francesca Bergamo, Sergio Ricci, Flavia Foca, Stefano Severi, Mauro Cives, Davide Campana, Nicola Silvestris, Angela Buonadonna, Maria Pia Brizzi, Francesca Spada, Sara Cingarlini, Lorenzo Antonuzzo, Davide Pastorelli
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-07-01
Online Access:	https://bmjopen.bmj.com/content/10/7/e034393.full